Family medical history revealed one case of malignant neoplasm. The patient's father, a long-term smoker, was diagnosed with lung cancer at the age of 53.
In July 2014, a second biopsy specimen was taken. Hematoxylin and eosin (H&E) staining revealed intensive infiltration of small to medium-sized lymphocytes intermingled with scattered histiocytes and plasma cells involving a deep portion of the dermis ( Figure 1A,B) . Immunohistochemistry demonstrated follicular T-helper phenotype of the lymphocytes (CD3+, CD4+, CD8−, CD7−, PD1−, CXCL13+ [ Figure 1C ], bcl6−, and TIA1−/+). No molecular studies have been undertaken to confirm monoclonality; however, loss of CD7, a pan-T-cell marker, seemed to be an indirect proof of malignant transformation, although not unequivocal determinant of TCR rearrangement. Epstein-Barr virus and cytomegalovirus status have not been analyzed.
Physical examination showed neither systemic symptoms nor lymphadenopathy. The results of laboratory examinations, including a complete blood cell count with differential count, liver function tests, renal function tests, and urinalysis, were all within normal limits. Computed tomography examination of the neck, chest, abdomen, and pelvis revealed no abnormalities. Bone marrow aspiration showed no evidence of malignancy. Relapse of HL was excluded.
Based on these findings, the patient was diagnosed as having PCSM-TCLPD, as it seemed to be most consistent diagnosis with the clinical and histological findings. He underwent surgical excision of the affected area but surgery turned out to be ineffective: The surgical wound was not healing, and the skin lesion developed again at the original site and gradually increased in size.
One year after surgical treatment, the patient returned to the clinic for assessment. Physical examination revealed a redlivid, ulcerative, solitary nodular infiltration of the skin, and subcutaneous tissue, 20 × 15 cm in diameter (Figure 2A,B) . Due to the infiltration, the right thigh was enlarged twice to its normal size, which impaired his movement. Staging for extracutaneous involvement was negative. The presence of ulcers was a factor which disqualified from radiotherapy. The patient was started on a course of cyclophosphamide (0.9 mg/kg/d po) and methylprednisolone (0.35 mg/kg/d po). After two weeks of treatment, 90% regression of the skin lesion was observed ( Figure 2C ). As such, a good response was observed during the follow-up, and methylprednisolone was gradually tapered and discontinued after eight weeks. Cyclophosphamide was tapered to 75 mg per day after 10 weeks. Four months after the initiation of cyclophosphamide therapy, the patient developed hemorrhagic cystitis and the drug had to be discontinued. As a consequence, the lesion relapsed in the same area over a period of two weeks grew up to 10 × 8 cm in size, and hard-to-heal wounds formed within the lesion. In May 2016, computed tomography of the abdomen and pelvis and laboratory tests demonstrated no abnormalities. The patient was put on a course of 20 mg oral methotrexate once a week for ten months, resulting in the disease stabilizing. Methotrexate was found to be clearly less effective than the combination of cyclophosphamide and methylprednisolone administered previously, with the 6-cm-sized infiltration persisting, despite the wounds within the lesion almost healing. Therefore, in March 2017, methotrexate therapy was interrupted and the patient started radiation therapy. In the third week of radiotherapy, the lesion decreased to 2.5 cm in size. Subsequently, the tumor disappeared and only healing persisted in the place of tumor. The patient has been seen in our outpatient clinic in November 2018 without any symptoms of lymphoma.
| DISCUSSION
We would like to note a possible link between HL treatment and PCSM-TCLPD in the presented case. Many reports demonstrate over twofold increased risk of subsequent malignancies for HL survivors compared with general population. The relative risk of subsequent malignancy increased between five and nine years after chemotherapy alone and remained elevated for 25 years and longer when combined therapies (with radiotherapy) were used. The risk was markedly higher when a chemotherapy included alkylators, as in our case. [7] [8] [9] In addition, in our case the subsequent tumor developed in the area exposed to radiation during HL treatment, which might be responsible for the unusual localization.
The lesion size in case described herein was larger than other reported cases (1-2.5 cm), it might be one of the possible reason why the first-line therapy failed. 5, 6 Cyclophosphamide is believed to be an effective form of second-line therapy for PCSM-TCLPD, when given as a single chemotherapeutic agent. Only few reports of this therapy for PCSM-TCLPD exist in the literature. 4 ,10 Wawrzycki at al. observed good response in the case presenting with widespread nodules after ineffective PUVA therapy. 10 AlbertiVioletti et al 4 described two cases with initial response and relapse in further course, and the third patient demonstrated progression. Not only is this the first case report of the development of PCSM-TCLPD as secondary neoplasm in a patient previously treated for HL, it also describes an atypical presentation of this rare entity.
